Diabetes Innovations Under Abbott's New Leadership: Exploration of Latest Sensors, Strategic Partnerships, and Type 2 Coverage
In a significant development for the diabetes community, Abbott, a leading healthcare company, is set to launch its glucose-ketone continuous monitoring sensor in 2026. This innovative sensor, designed to continuously monitor both glucose and ketone levels, promises to improve diabetes management by preventing diabetic ketoacidosis (DKA).
The sensor will integrate with multiple devices, including Tandem Diabetes Care pumps and Sequel Med Tech devices, as well as Medtronic and Beta Bionics, according to recent announcements. Tandem Diabetes Care has confirmed plans to incorporate this Abbott sensor into their insulin pumps, while Sequel Med Tech is also set to support this sensor integration.
The American Diabetes Association (ADA) guidelines have changed to consider Continuous Glucose Monitoring (CGM) for people who aren't on insulin, a move that Abbott sees as a significant step forward. The large, underpenetrated total addressable market of people managing their diabetes but not using insulin is growing rapidly.
Abbott's new sensor is part of the near-future rollout of advanced diabetes monitoring technologies. The company is excited about bringing to market its dual glucose-ketone sensor, which they believe has a tremendous amount of promise in addressing rising ketones that can cause ketoacidosis.
Chris Scoggins, the executive vice president of diabetes care at Abbott, expressed enthusiasm about the potential of AI to advance healthcare on multiple fronts. Abbott is also interested in partnership, algorithm support, and helping people to ease their burden of decision making on connected devices.
The integration with Tandem around the glucose-ketone sensor is expected to bring exciting news at the American Diabetes Association's Scientific Sessions. Access to the CGM category on the commercial payer side has doubled in the last four years, and some individual states on the Medicaid side are changing their access to follow the new ADA guidelines.
This development is a significant stride towards improved diabetes management and prevention of DKA. With the integration of Abbott's glucose-ketone sensor with various devices, people with diabetes can look forward to a more connected and efficient management of their condition.
- In the realm of healthcare, particularly medical-conditions like diabetes, innovation is on the horizon with Abbott leading the charge in 2026, set to launch its glucose-ketone continuous monitoring sensor.
- With a focus on healthcare and technology, Abbott's invention will monitor both glucose and ketone levels, offering potential to significantly improve diabetes management and prevent Diabetic Ketoacidosis (DKA).
- The sensor will collaborate with various devices in the medtech industry, such as Tandem Diabetes Care pumps, Sequel Med Tech devices, Medtronic, and Beta Bionics.
- In an effort to cater to a growing market, Abbott's sensor aligns with the revised American Diabetes Association (ADA) guidelines, focusing on Continuous Glucose Monitoring (CGM) for those not using insulin.
- As part of the coming wave of advanced diabetes monitoring technologies, Abbott is optimistic about their dual glucose-ketone sensor, which holds promise in addressing rising ketone levels and DKA.
- Addressing the future of combined healthcare and technology, Chris Scoggins, Abbott's executive vice president of diabetes care, sees great potential for AI in enhancing healthcare in numerous aspects.
- Collaboration is on the horizon as Abbott aims to partner with industry counterparts, support algorithms, and assist individuals in simplifying their decision-making processes on connected devices.
- At the upcoming American Diabetes Association's Scientific Sessions, exciting news surrounding the integration of Tandem and Abbott's glucose-ketone sensor is anticipated.
- The integration of Abbott's glucose-ketone sensor with various devices signifies a crucial development for diabetes management, allowing people with diabetes to anticipate a more streamlined and efficient management of their health and wellness.
